REFERENCES
- Bommelaer G, Poynard T, Le Pen C, et al. Prevalence of irritable bowel
syndrome (IBS) and variability of diagnostic criteria. Gastroenterol
Clin Biol 2004; 28: 554-61
- Bulut, N. S., & Arpacıoğlu, Z. B. (2020). Acute onset psychosis with
complex neurobehavioural symptomatology following the intramuscular
injection of hyoscine butylbromide: a case report with an overview of
the literature. European journal of hospital pharmacy : science
and practice , ejhpharm-2020-002583. Advance online publication.
https://doi.org/10.1136/ejhpharm-2020-002583
- Evangelista S. Quaternary ammonium derivatives as spasmolytics for
irritable bowel syndrome. Curr Pharm Des 2004; 10: 3561-8
- Falch, C., Vicente, D., Häberle, H., Kirschniak, A., Müller, S.,
Nissan, A., & Brücher, B. L. (2014). Treatment of acute abdominal
pain in the emergency room: a systematic review of the
literature. European journal of pain (London,
England) , 18 (7), 902–913.
https://doi.org/10.1002/j.1532-2149.2014.00456.x
- Herxheimer A, Haefeli L. Human pharmacology of hyoscine butylbromide.
Lancet 1966; 2: 418-21
- Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the
irritable bowel syndrome: a systematic review of ran- domized,
controlled trials. Ann Intern Med 2000; 133: 136-47
- Lesbros-Pantoflickova D, Michetti P, Fried M, et al. Meta- analysis:
the treatment of irritable bowel syndrome. Aliment Pharmacol Ther
2004; 20: 1253-69
- Maxion-Bergemann S, Thielecke F, Abel F, et al. Costs of irritable
bowel syndrome in the UK and US. Pharmacoeco- nomics 2006; 24: 21-37
- Mueller-Lissner S, Tytgat GN, Paulo LG, et al. Placebo- and
paracetamol-controlled study on the efficacy and tolerability of
hyoscine butylbromide in the treatment of patients with recurrent
crampy abdominal pain. Aliment Pharmacol Ther 2006; 23: 1741-8
- Müller-Krampe, B., Oberbaum, M., Klein, P., & Weiser, M. (2007).
Effects of Spascupreel versus hyoscine butylbromide for
gastrointestinal cramps in children. Pediatrics international :
official journal of the Japan Pediatric Society , 49 (3),
328–334. https://doi.org/10.1111/j.1442-200X.2007.02382.x
- Poonai, N., Kumar, K., Coriolano, K., Thompson, G., Brahmbhatt, S.,
Dzongowski, E., Stevens, H., Gupta, P., Miller, M., Elsie, S., Ashok,
D., Joubert, G., Lim, R., Bütter, A., & Ali, S. (2020). Hyoscine
butylbromide versus acetaminophen for nonspecific colicky abdominal
pain in children: a randomized controlled trial. CMAJ : Canadian
Medical Association journal = journal de l’Association medicale
canadienne , 192 (48), E1612–E1619.
https://doi.org/10.1503/cmaj.201055
- Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle
relaxants in the treatment of irritable bowel syndrome. Aliment
Pharmacol Ther 2001; 15: 355-61
- Quigley EMM, Locke GR, Mueller-Lissner S, et al. Prevalence and
management of abdominal cramping and pain: a multina- tional survey.
Aliment Pharmacol Ther 2006; 24: 411-9
- Sandler RS, Stewart WF, Liberman JN, et al. Abdominal pain, bloating,
and diarrhea in the United States: prevalence and impact. Dig Dis Sci
2000; 45: 1166-71
- Saps, M., Seshadri, R., Sztainberg, M., Schaffer, G., Marshall, B. M.,
& Di Lorenzo, C. (2009). A prospective school-based study of
abdominal pain and other common somatic complaints in
children. The Journal of pediatrics , 154 (3), 322–326.
https://doi.org/10.1016/j.jpeds.2008.09.047
- Scha ̵̈fer E, Ewe K. The treatment of irritable colon: efficacy and
tolerance of buscopan plus, buscopan, paracetamol and place- bo in
ambulatory patients with irritable colon [in German]. Fortschr Med
1990; 108 (25): 488-92
- Simre ̵́n M, Brazier J, Coremans G, et al. Quality of life and illness
costs in irritable bowel syndrome. Digestion 2004; 69: 254-61
- Tytgat GN. Hyoscine butylbromide: a review of its use in the treatment
of abdominal cramping and pain. Drugs . 2007;67(9):1343-1357.
doi:10.2165/00003495-200767090-00007